CRISM Therapeutics Corporation
CRTX.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £25 | £57 | £0 | £0 |
| % Growth | -56.4% | – | – | – |
| Cost of Goods Sold | £4 | £41 | £0 | £0 |
| Gross Profit | £21 | £17 | £0 | £0 |
| % Margin | 84% | 28.9% | – | – |
| R&D Expenses | £168 | £0 | £0 | £0 |
| G&A Expenses | £512 | £1,782 | £1,738 | £938 |
| SG&A Expenses | £512 | £1,782 | £1,806 | £1,300 |
| Sales & Mktg Exp. | £0 | £0 | £68 | £362 |
| Other Operating Expenses | -£77 | £477 | £418 | £0 |
| Operating Expenses | £603 | £2,259 | £2,224 | £1,300 |
| Operating Income | -£582 | -£2,259 | -£2,224 | -£1,300 |
| % Margin | -2,328% | -3,937.9% | – | – |
| Other Income/Exp. Net | -£11 | £336 | -£381 | -£1 |
| Pre-Tax Income | -£593 | -£1,923 | -£2,605 | -£1,302 |
| Tax Expense | £0 | £204 | £331 | £241 |
| Net Income | -£607 | -£9,647 | -£2,446 | -£1,542 |
| % Margin | -2,428% | -16,816.6% | – | – |
| EPS | -0.1 | -0.068 | -0.28 | -0.18 |
| % Growth | -46.5% | 75.7% | -55.6% | – |
| EPS Diluted | -0.1 | -0.27 | -0.28 | -0.18 |
| Weighted Avg Shares Out | 6,080 | 8,705 | 8,698 | 8,624 |
| Weighted Avg Shares Out Dil | 6,076 | 8,705 | 8,698 | 8,624 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £11 | £0 | £0 | £0 |
| Depreciation & Amortization | £16 | -£175 | £277 | £277 |
| EBITDA | -£566 | -£2,259 | -£1,806 | -£1,300 |
| % Margin | -2,264% | -3,937.9% | – | – |